casemark/skills/adverse-event-reporting-policy

Adverse Event Reporting Policy

Drafts a binding AE reporting policy meeting FDA requirements and ICH standards for pharma, biotech, CROs, and healthcare organizations conducting or sponsoring clinical research.

Prerequisites

Gather before drafting. If any item is missing, pause and ask — do not assume.

1. Organization type — pharmaceutical sponsor, CRO, healthcare system, academic medical center, or combination
2. Product portfolio — IND products (Phase I–IV), approved drugs, biologics, devices, combination products, REMS-covered products
3. Geographic footprint — domestic only vs. multi-jurisdictional (EU, Japan, Canada, etc.)
4. Therapeutic areas — flag specialized populations: oncology, vaccines, biologics, pediatrics
5. Existing SOPs — current pharmacovigilance SOPs, IRB agreements, DSMB charters to cross-reference

Step 1: Introduction & Compliance Statement

• Cite controlling regulations:
• 21 CFR 312.32 — IND safety reporting
• 21 CFR 314.80 — Postmarketing adverse drug experience
• ICH E2A — Clinical safety data management
• 21 CFR 803 — Medical device reporting (if applicable)
• Applicable state and international requirements
• Effective date, review cycle (annual minimum), approval authority
• Binding compliance statement: policy adherence is condition of employment; violations may constitute federal law violations

Step 2: Definitions

Include at minimum:

SAE Seriousness Criteria (6 FDA/ICH):

1. Death
2. Life-threatening (immediate risk at time of event)
3. Inpatient hospitalization or prolongation
4. Persistent/significant disability or incapacity
5. Congenital anomaly/birth defect
6. Important medical event requiring intervention to prevent serious outcome

Step 3: Scope

Covered activities: Phase I–IV clinical trials; post-marketing surveillance; expanded access/compassionate use; investigator-initiated studies

Covered products: IND products, approved drugs, biologics, vaccines, gene therapies, medical devices (IDE), combination products, REMS-covered products

Geographic scope: Specify domestic-only vs. global; address how international events feed FDA reporting; handle countries where product is unapproved

Temporal boundaries:

• Begins: informed consent signature or first dose
• Ends: per protocol follow-up period (specify days; address long half-life/delayed-effect products)

Exclusions:

Step 4: Roles & Responsibilities

Step 5: AE Identification & Assessment

Active surveillance: Structured patient interviews at each contact; lab values vs. protocol ranges and clinically significant change thresholds; physical examination with baseline comparison; concomitant medication review (may indicate unreported AE).

Passive surveillance: Dedicated patient reporting line/email/portal; external provider reporting pathway; EHR alert integration (hospitalizations, ED visits, critical labs) where feasible.

Causality assessment — document each factor:

Use validated tool (Naranjo Scale or WHO-UMC). Document algorithm applied and narrative rationale — not just final conclusion.

Severity grading: CTCAE or protocol-specified scale; document grade and supporting clinical findings.

Enhanced monitoring populations: Pediatric (developmental); pregnant (maternal/fetal); elderly with polypharmacy (attribution complexity); immunocompromised (atypical presentations).

Step 6: Reporting Timelines & Submission

Expedited IND Safety Reports (21 CFR 312.32):

Other reporting obligations:

• Annual IND Safety Reports — within 60 days of IND anniversary; tabular AE summaries, narrative SAE descriptions, signal analysis, updated risk-benefit
• IRB/IEC — same timeline as FDA or 24 hours per IRB requirements, whichever more stringent; all SAEs regardless of causality
• DSMB/IDMC — per charter; unblinded data; expedited notification for predefined stopping rules

Postmarketing (21 CFR 314.80): 15-day alert reports for serious unexpected AEs; PADERs per approved schedule.

Submission mechanics: FDA Electronic Submission Gateway; Form 3500A; ICH E2B(R3) format. Backup: telephone for urgent situations. Retain all submission confirmations and FDA acknowledgment receipts.

Multi-jurisdictional overlay:

Step 7: Documentation Standards

Source documents: Created in real-time or within 24 hours. Corrections by single strikethrough (original legible), correct entry, initials, date — no deletions or obliteration.

Required AE record elements:

• Date/time of onset (maximum available precision)
• Clinical description: signs/symptoms, severity (CTCAE grade), frequency, duration, anatomical location
• Causality assessment: algorithm used, each factor, narrative rationale, final determination
• Seriousness determination: specific criterion/criteria met
• Expectedness determination: IB/labeling section consulted
• Actions taken: dose modifications, discontinuation, concomitant treatments, procedures
• Hospitalizations: dates, facility
• Outcome: recovered/resolved | recovering/resolving | not recovered | recovered with sequelae | fatal
• Regulatory submission: date, submission number, FDA acknowledgment

Record retention:

Storage: Access-controlled; audit trail with user ID and timestamps; geographically separate backups; validated electronic systems (21 CFR Part 11 where applicable).

Step 8: Training & Competency

Initial training (before assuming AE responsibilities): Regulatory framework (21 CFR 312.32, 314.80, ICH E2A); organizational policy and workflows; event identification; causality assessment with case exercises; documentation standards; reporting timelines and consequences of missed deadlines.

Annual refresher: Regulatory updates, audit lessons learned (anonymized), process revisions.

Role-specific advanced training:

Competency assessment: Written exam (minimum passing score); practical case scenario evaluation; supervised performance period before independent authorization.

Annual certification: Written attestation of policy awareness, training completion, and compliance commitment. Failure suspends research privileges.

Step 9: Quality Assurance & Enforcement

Audit program (minimum annually; risk-based frequency):

• Timeline compliance: site awareness → Safety Officer → FDA submission
• Documentation completeness and causality rationale adequacy
• Causality consistency (independent medical review of sample)
• Submission accuracy vs. source documents

KPIs (quarterly senior management review):

Root cause analysis: Required for all timeline failures, missed reports, and quality deficiencies. Address systemic causes (training, resources, process design). CAPA with assigned owner and target date.

Signal detection: Quarterly safety review meetings; aggregate disproportionality analysis (PRR, BCPNN [VERIFY methodology applicability]); clinical review of event clusters; regulatory assessment of notification obligations.

Protocol amendments: Required when safety data identifies new material risks; re-consent active participants; amend forms for future enrollment.

Enforcement:

• Violations subject to progressive discipline up to termination; knowing/willful failures may constitute federal law violations
• Non-retaliation: No adverse action for good-faith AE reporting; over-reporting preferred to under-reporting
• Anonymous reporting pathway required (compliance officer, hotline, legal counsel)
• Manager performance evaluations include AE compliance metrics

Quality Audit

Before finalizing, verify: